MDWD250117P19000
- 0.00
- 0.000.00%
MediWound Newsroom
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company's Future
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Strategic Growth and Market Potential Drive Buy Rating for MediWound Despite Revenue Decline
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $25
MediWound Ltd. Advances Development With EscharEx IND Submission Planned for Year-End and NexoBrid FDA Pediatric Approval
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
Express News | Mediwound Shares Fall 4.8% Premarket After Q3 Results
MediWound Advances With FDA Approval and New Funding
MediWound GAAP EPS of -$0.98 Misses by $0.53, Revenue of $4.35M Misses by $1.66M
MediWound | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Flash (MDWD) MEDIWOUND Posts Q3 Revenue $4.4M, Vs. Street Est of $6.0M
Express News | Mediwound : Anticipates $20 Mln in Total Revenue for 2024
Express News | Mediwound Q3 Gross Profit USD 700 Thousand
MediWound 3Q Loss $26.3M >MDWD
MediWound 3Q Loss/Shr 98c >MDWD